From Band-Aids to biotech, Johnson & Johnson became an American icon - USA Today
From Band-Aids to biotech, Johnson & Johnson became an American icon USA Today
Johnson & Johnson Company News
What you need to know about Johnson & Johnson’s first-quarter 2026 earnings report - Johnson & Johnson
What you need to know about Johnson & Johnson’s first-quarter 2026 earnings report Johnson & Johnson
J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde - Fierce Pharma
J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde Fierce Pharma
Johnson & Johnson Financial Chief Sees ‘Clear Line of Sight’ to Double-Digit Growth by 2030 - Barron's
Johnson & Johnson Financial Chief Sees ‘Clear Line of Sight’ to Double-Digit Growth by 2030 Barron's
J&J tops first-quarter profit estimates even as Stelara sales plunge - Reuters
J&J tops first-quarter profit estimates even as Stelara sales plunge Reuters
What Johnson & Johnson Earnings Signal for Healthcare ETFs - ETF Database
What Johnson & Johnson Earnings Signal for Healthcare ETFs ETF Database
Johnson & Johnson Reports Strong Q1 Earnings, Raises Its 2026 Guidance - VisionMonday.com
Johnson & Johnson Reports Strong Q1 Earnings, Raises Its 2026 Guidance VisionMonday.com
How Johnson & Johnson helped shape America - Asbury Park Press
How Johnson & Johnson helped shape America Asbury Park Press
Johnson & Johnson $JNJ Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Johnson & Johnson $JNJ Shares Sold by Robeco Institutional Asset Management B.V. MarketBeat
Why Dow Jones' J&J Is Wavering Despite Its First-Quarter Beat And Raise - Investor's Business Daily
Why Dow Jones' J&J Is Wavering Despite Its First-Quarter Beat And Raise Investor's Business Daily
J&J leans on Tremfya, cancer drugs to overcome Stelara losses - BioPharma Dive
J&J leans on Tremfya, cancer drugs to overcome Stelara losses BioPharma Dive
J&J’s cardiovascular unit stands out again in Q1 - MedTech Dive
J&J’s cardiovascular unit stands out again in Q1 MedTech Dive
Johnson & Johnson Bets Big on Next-Gen Growth - TipRanks
Johnson & Johnson Bets Big on Next-Gen Growth TipRanks
Johnson & Johnson ups 2026 outlook on Q1 beats, MedTech sales rise 7.7% - MassDevice
Johnson & Johnson ups 2026 outlook on Q1 beats, MedTech sales rise 7.7% MassDevice
J&J’s First-Quarter Sales Grow on Cancer-Drug Strength - WSJ
J&J’s First-Quarter Sales Grow on Cancer-Drug Strength WSJ
Johnson & Johnson beats Q1 2026 earnings estimates and raises full-year outlook - qz.com
Johnson & Johnson beats Q1 2026 earnings estimates and raises full-year outlook qz.com
Rep. Thomas H. Kean, Jr. Sells Johnson & Johnson (NYSE:JNJ) Stock - MarketBeat
Rep. Thomas H. Kean, Jr. Sells Johnson & Johnson (NYSE:JNJ) Stock MarketBeat
Johnson & Johnson $JNJ Shares Acquired by Ritholtz Wealth Management - MarketBeat
Johnson & Johnson $JNJ Shares Acquired by Ritholtz Wealth Management MarketBeat
Johnson & Johnson (NYSE:JNJ) Increases Dividend to $1.34 Per Share - MarketBeat
Johnson & Johnson (NYSE:JNJ) Increases Dividend to $1.34 Per Share MarketBeat
Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results - MarketBeat
Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results MarketBeat
Johnson & Johnson (JNJ) Reports Strong Q1 2026 Earnings and Rais - GuruFocus
Johnson & Johnson (JNJ) Reports Strong Q1 2026 Earnings and Rais GuruFocus
Johnson & Johnson raises guidance for 2026 on strong start to the year - MarketWatch
Johnson & Johnson raises guidance for 2026 on strong start to the year MarketWatch
Earnings call transcript: Johnson & Johnson Q1 2026 earnings beat expectations - Investing.com
Earnings call transcript: Johnson & Johnson Q1 2026 earnings beat expectations Investing.com
Johnson and Johnson Raises Dividend for 64th Consecutive Year - 24/7 Wall St.
Johnson and Johnson Raises Dividend for 64th Consecutive Year 24/7 Wall St.
With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026 - BioSpace
With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026 BioSpace
Johnson & Johnson Q2 Earnings Review: Why You Should Be Buying The Stock Today (NYSE:JNJ) - Seeking Alpha
Johnson & Johnson Q2 Earnings Review: Why You Should Be Buying The Stock Today (NYSE:JNJ) Seeking Alpha
Johnson & Johnson increases revenue by 10%, but profit falls 52% to 4.8 billion in the 1st quarter of 2026 - MVNU
Johnson & Johnson increases revenue by 10%, but profit falls 52% to 4.8 billion in the 1st quarter of 2026 MVNU
J&J's Immunology and Oncology Drug Portfolios and Diversified Medtech Business Support a Wide Moat - Morningstar
J&J's Immunology and Oncology Drug Portfolios and Diversified Medtech Business Support a Wide Moat Morningstar
RBC Capital raises Johnson & Johnson stock price target on strong Q1 beat - Investing.com
RBC Capital raises Johnson & Johnson stock price target on strong Q1 beat Investing.com
Johnson & Johnson Dividend Streak Extends As New Therapies Support Outlook - simplywall.st
Johnson & Johnson Dividend Streak Extends As New Therapies Support Outlook simplywall.st
Johnson & Johnson beats expectations on strong cancer drug sales - medwatch.com
Johnson & Johnson beats expectations on strong cancer drug sales medwatch.com
J&J among Fortune 2026 America’s Most Innovative Companies list - Johnson & Johnson
J&J among Fortune 2026 America’s Most Innovative Companies list Johnson & Johnson
MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat - FinancialContent
MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat FinancialContent
The New J&J: A 2026 Deep Dive into the Global Healthcare Titan - FinancialContent
The New J&J: A 2026 Deep Dive into the Global Healthcare Titan FinancialContent
Johnson & Johnson Q1 preview: What to expect - Seeking Alpha
Johnson & Johnson Q1 preview: What to expect Seeking Alpha
Johnson & Johnson Q1 Earnings Call Highlights - MarketBeat
Johnson & Johnson Q1 Earnings Call Highlights MarketBeat
Johnson & Johnson (JNJ) is Gaining from Its Strong Innovative Medicine Growth - Yahoo Finance
Johnson & Johnson (JNJ) is Gaining from Its Strong Innovative Medicine Growth Yahoo Finance
J&J lifts 2026 forecast after $24.1B quarter and new approvals - Stock Titan
J&J lifts 2026 forecast after $24.1B quarter and new approvals Stock Titan
Johnson and Johnson Raises Dividend for 64th Consecutive Year - Yahoo Finance
Johnson and Johnson Raises Dividend for 64th Consecutive Year Yahoo Finance
Guggenheim reiterates Johnson & Johnson stock rating on solid results By Investing.com - Investing.com Canada
Guggenheim reiterates Johnson & Johnson stock rating on solid results By Investing.com Investing.com Canada